Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212
J. Ludovic Croxford, Stephen D. Miller
J. Ludovic Croxford, Stephen D. Miller
Published April 15, 2003
Citation Information: J Clin Invest. 2003;111(8):1231-1240. https://doi.org/10.1172/JCI17652.
View: Text | PDF
Categories: Article Autoimmunity

Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212

Abstract

Theiler murine encephalomyelitis virus–induced demyelinating disease (TMEV-IDD) is a mouse model of chronic-progressive multiple sclerosis (MS) characterized by Th1-mediated CNS demyelination and spastic hindlimb paralysis. Existing MS therapies reduce relapse rates in 30% of relapsing-remitting MS patients, but are ineffective in chronic-progressive disease, and their effects on disability progression are unclear. Experimental studies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in chronic-relapsing experimental autoimmune encephalomyelitis. Cannabinoids, however, have reported immunosuppressive properties. We show that the cannabinoid receptor agonist, R(+)WIN55,212, ameliorates progression of clinical disease symptoms in mice with preexisting TMEV-IDD. Amelioration of clinical disease is associated with downregulation of both virus and myelin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-γ production) and the inhibition of CNS mRNA expression coding for the proinflammatory cytokines, TNF-α, IL1-β, and IL-6. Clinical trials investigating the therapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study demonstrates that they may also have potent immunoregulatory properties.

Authors

J. Ludovic Croxford, Stephen D. Miller

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Cannabinoid receptor agonism ameliorates the clinical severity of establ...
Cannabinoid receptor agonism ameliorates the clinical severity of established TMEV-induced demyelinating disease. Treatment with R(+)WIN55,212 (filled circles) inhibits TMEV-induced clinical disease when administered, at the time of infection (a), at the onset of clinical disease (b), or during established disease (c). Rx, duration of administration of WIN55,212 to mice. *Significant inhibition (P < 0.05) of clinical disease score in R(+)WIN55,212-treated mice compared with S(–)WIN55,212 (open circles) or untreated TMEV mice (filled triangles). Data are representative of three separate experiments.